Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928411 | 0.87 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL15476104 | 0.87 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL29998990 | 0.87 | PDE10A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL6201686 | 0.85 | KMT2A (0.45) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30778281 | 0.80 | TRPV1 (0.57) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL1433407 | 0.80 | TRPV1 (0.57) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25182135 | 0.80 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL31104968 | 0.80 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL23603467 | 0.78 | CNR1 (0.47) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL22470063 | 0.77 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2356125-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010002971-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNB2 | KMT2A 4151/4885MEN1 3953/4885SMN1; SMN2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.